ALIVE Israel HealthTech Fund

ALIVE Israel HealthTech Fund, headquartered in Tel Aviv, is a mid-to-late-stage healthtech investor that occupies a relatively rare slot in the Israeli capital stack. Most local funds concentrate on seed and Series A. ALIVE writes larger checks into companies that have already proved early commercial traction, and it does so with a structural advantage: a partnership network of hospitals and HMOs that provides both clinical validation and pilot infrastructure.

The fund’s thesis covers medical devices and digital health, with explicit interest in AI-enabled platforms across imaging, clinical decision support, remote care, and operational software for providers. Companies that fit ALIVE typically have a CE mark or FDA clearance in hand or near at hand, paying customers, and a story about how the next round of capital accelerates an existing commercial motion rather than tests an unproven hypothesis. The hospital partnership network is most useful for companies whose product requires real clinical workflow integration before scaling, which is to say most regulated digital health.

Check sizes range from $5M to $25M, with Series B, Series C, and growth being the typical entry points. Geography centers on Israeli companies, but the fund’s frame of reference is global commercial scale, particularly in the US, Europe, and selected Asian markets. ALIVE participates as a lead or co-lead in priced rounds, and it brings strong syndicate partners from Israeli and international healthtech firms when needed. Reserves are sized to support follow-on through subsequent rounds where the company is performing.

The team is composed of investment professionals with backgrounds in healthcare investing, operations, and the Israeli hospital and HMO systems, supplemented by clinical advisors drawn from the partner institutions. The fund tends to operate as an active board investor, helpful around US commercial expansion, payer strategy, and the practicalities of running clinical validations through Israeli partner systems.

Founders should approach ALIVE when a meaningful commercial story exists, regulatory approvals are mature, and the next round is intended to fund expansion rather than discovery. Introductions through Israeli VCs, hospital executives, or portfolio CEOs are the highest-yield path. Direct outbound from a credible founder with traction is also a reasonable approach, given the fund’s relatively narrow stage focus. The right time to engage is roughly six to twelve months before a planned round, allowing time for the fund to observe progress, run pilots through partner institutions, and form conviction. Companies still in the regulatory submission phase, with limited revenue, or with unclear go-to-market are better served raising elsewhere first and returning when commercial signals are stronger. For founders running scalable healthtech businesses with a need for clinical validation infrastructure as well as capital, ALIVE is one of the most operationally useful late-stage partners in Israel.